Array BioPharma: FDA accepts New Drug Application for melanoma

Array BioPharma: FDA accepts New Drug Application for melanoma

BOULDER -- Array BioPharma (Nasdaq: ARRY) today announced the FDA has accepted its New Drug Application (NDA) for binimetinib with a target action date under the Prescription Drug User Fee Act... Read More

Thursday September 1, 2016 0 comments Tags: Boulder, Array BioPharma, binimetinib, Dr. Victor Sandor

Array BioPharma submits New Drug Application for binimetinib to FDA

Array BioPharma submits New Drug Application for binimetinib to FDA

BOULDER -- Array BioPharma (Nasdaq:ARRY) announced it submitted a New Drug Application (NDA) to the FDA for binimetinib in patients with advanced NRAS -mutant melanoma. The submission is... Read More

Friday July 1, 2016 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, binimetinib

Array BioPharma closes agreement with Pierre Fabre to commercialize cancer products

Array BioPharma closes agreement with Pierre Fabre to commercialize cancer products

BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) today announced closing a definitive agreement with France-based Pierre Fabre following approval of the agreement by the European Commission on... Read More

Monday December 21, 2015 0 comments Tags: Boulder, Array BioPharma, Pierre Fabre, binimetinib, encorafenib

Array BioPharma partners with Pierre Fabre to globally develop and market cancer drugs

Array BioPharma partners with Pierre Fabre to globally develop and market cancer drugs

BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) and France-based Pierre Fabre are collaborating to globally develop and commercialize Arrays late-stage novel oncology products, binimetinib and... Read More

Tuesday November 17, 2015 0 comments Tags: Boulder, Array BioPharma, Pierre Fabre, Ron Squarer, binimetinib, encorafenib

Array BioPharma to regain rights to cancer-fighting drug under agreement with Novartis International

Array BioPharma to regain rights to cancer-fighting drug under agreement with Novartis International

BOULDER - Array BioPharma Inc. (NASDAQ: ARRY) announced it has reached a definitive agreement with Novartis International Pharmaceutical Ltd. to regain full worldwide rights to binimetinib. ... Read More

By: InnovatioNews Thursday December 4, 2014 0 comments Tags: Array BioPharma, binimetinib, Boulder, Novartis, Ron Squarer